Figure 6: Decreased thymic selection of V α 14 NKT cells in CD1-TD mice. In summary, the CD1-TD knock-in mouse showed selective defects in CD1d-mediated antigen presentation. It allowed the ...

Yuan Liu from Georgia State University reports that intratumoral SIRPα-deficient macrophages activate tumor ... excellent antigen presenting cells that conduct immunogenic antigen presentation ...

Tumor antigens are captured and displayed by antigen processing and presentation machinery (APM) on the cell surface by HLA-I, making it possible for CD8 + T cells to eliminate cancer cells.

(3) Genetic modification of the T cells is performed by inserting the CAR gene, enabling them to recognize tumor-specific antigens. (4) CAR-T cells are expanded ex vivo to achieve sufficient ...

To provide TCR therapy, one must identify and clone the DNA sequence encoding a T-cell receptor that is known to react to tumor antigen. The TCR can target either intra- or extracellular ...

YTHDF1 controls the level of proteases that destroy potential tumor antigens. This limits their presentation to T cells. These limits were a problem, He said. But when he and his colleagues ...

CAR+ cells denote CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III (EGFRvIII) tumor-specific ...

including those involved in antigen presentation and immune surveillance. Notably, this mechanistic interaction was found to be cell- and cancer-type agnostic, providing a generalized mechanism of ...

Their approach uses a two-step process: first, modifying tumor proteins with a molecule called AHPC to enhance antigen presentation, and second, packaging the modified proteins into lipid ...

Cancer cells also erroneously express as ... "Notably, NeoDisc can also detect potential defects in the machinery of antigen presentation, alerting vaccine designers and clinicians to a key ...

Details of the presentation are ... CB21 is a highly-potent T-cell engager molecule that targets LY6G6D, an emerging, next-generation tumor-specific antigen for treating colorectal cancer (CRC ...